Revista Espanola de Enfermedades Digestivas · Nov 12, 2026

Real world data to improve hepatocellular carcinoma surveillance in cirrhosis

By Rojas Á, Gutiérrez Álvarez I, Gil-Gómez A et al.

BACKGROUND AND AIMS: Surveillance for hepatocellular carcinoma (HCC) remains suboptimal due to poor adherence and limited diagnostic accuracy. We aimed to develop and validate a simple risk score to predict HCC in patients with cirrhosis. METHODS: A total of 667 patients with cirrhosis were followed for up to 60 months or until HCC development, liver transplantation, or death. A prognostic model was derived using multivariable Cox regression. Discrimination was assessed by Harrell's C-index and time-dependent area under the curve (tAUC), calibration by calibration slope and Brier score, and clinical utility by decision curve analysis. Competing-risk analyses accounted for liver transplantation and death. External validation was performed in 18,856 patients with cirrhosis from the Andalusian Population Health Database. RESULTS: The A3BS score (age, sex, AST, albumin, and bilirubin) demonstrated good discrimination, with C-index values ranging from 0.73 to 0.76 at 12, 24, 36, and 60 months. Patients in the high-risk group had a substantially higher 60-month cumulative incidence of HCC than those in the low-risk group (32% vs. 9%) and a fourfold increased risk of HCC (sHR 4.0, 95% CI 2.2-7.5; p<0.001). Importantly, patients classified as low risk had a very low probability of developing HCC, with a negative predictive value of 96.5%. Calibration analyses demonstrated good agreement between predicted and observed outcomes and low prediction error, while decision curve analysis confirmed clinical benefit across relevant risk thresholds. External validation confirmed consistent performance (tAUC 0.66 at 36 and 60 months). Predictive performance was particularly favorable in women and individuals younger than 60 years. CONCLUSIONS: A3BS is a simple five-variable score that provides reliable HCC risk stratification across cirrhosis etiologies and identifies a large subgroup of patients at very low risk of HCC, supporting personalized surveillance strategies and more efficient allocation of healthcare resources.

doi.org/10.17235/reed.2026.12131/2026PubMed 43018376Biomarkers

AgingResearch.News